McKesson MCK Business Segments
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Total revenues by Business | |||||
| Medical-Surgical Solutions | $11.51B+1.1% | $11.38B+0.7% | $11.31B+1.8% | $11.11B-4.3% | |
| North American Pharmaceutical | $336.65B+10.6% | $304.51B+16.5% | $261.37B— | —— | |
| Oncology & Multispecialty | $48.42B+31.4% | $36.86B+20.9% | $30.49B— | —— | |
| Prescription Technology Solutions | $5.81B+11.3% | $5.22B+9.4% | $4.77B+8.7% | $4.39B+13.5% | |
| Subtotal by Business | |||||
| Medical-Surgical Solutions | $938M+21.0% | $775M-18.8% | $955M— | —— | |
| North American Pharmaceutical | $3.66B+24.2% | $2.95B+26.0% | $2.34B— | —— | |
| Oncology & Multispecialty | $1.15B+49.8% | $767M+8.5% | $707M— | —— | |
| Prescription Technology Solutions | $1.04B+19.3% | $875M+4.8% | $835M— | —— | |
| Total other segment expense, net by Business | |||||
| Medical-Surgical Solutions | $10.57B-0.4% | $10.61B+2.5% | $10.35B+3.6% | $9.99B— | |
| North American Pharmaceutical | $332.99B+10.4% | $301.56B+16.4% | $259.03B— | —— | |
| Oncology & Multispecialty | $47.27B+31.0% | $36.1B+21.2% | $29.78B— | —— | |
| Prescription Technology Solutions | $4.76B+9.7% | $4.34B+10.3% | $3.93B+3.0% | $3.82B— | |
| Revenue derived from services (less than) (as a percent) by Business | |||||
| Prescription Technology Solutions | 118%0.0pp | 118%— | —— | —— | |
| Total segment expenditures for long-lived assets by Business | |||||
| Medical-Surgical Solutions | $94M-42.3% | $163M+2.5% | $159M— | —— | |
| North American Pharmaceutical | $334M+37.4% | $243M+52.8% | $159M— | —— | |
| Oncology & Multispecialty | $78M-11.4% | $88M-8.3% | $96M— | —— | |
| Prescription Technology Solutions | $4M-63.6% | $11M-64.5% | $31M— | —— | |
| Other by Business | |||||
| Medical-Surgical Solutions | $2M+200% | -$2M— | $0— | $0— | |
| Oncology & Multispecialty | $0+100% | -$1M— | —— | —— | |
| Total segment depreciation and amortization by Business | |||||
| Medical-Surgical Solutions | $96M+4.3% | $92M+12.2% | $82M+2.5% | $80M-38.0% | |
| North American Pharmaceutical | $134M-13.5% | $155M-21.3% | $197M— | —— | |
| Oncology & Multispecialty | $240M+62.2% | $148M+8.0% | $137M— | —— | |
| Prescription Technology Solutions | $82M-4.7% | $86M+2.4% | $84M+9.1% | $77M-6.1% | |
| Foreign currency translation adjustments, net by Business | |||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | |
| Prescription Technology Solutions | $0— | $0— | —— | —— | |
| Total reserve balance by Business | |||||
| Medical-Surgical Solutions | $112M-67.5% | $345M+3,733% | $9M+50.0% | $6M-14.3% | |
| Prescription Technology Solutions | $4M-66.7% | $12M— | —— | —— | |
| Other adjustments by Business | |||||
| Medical-Surgical Solutions | $0— | —— | $0— | $0— | |
| Prescription Technology Solutions | -$1M— | —— | —— | —— | |
| Non-cash charges by Business | |||||
| Medical-Surgical Solutions | -$8M-157% | $14M— | $0-100% | $5M— | |
| Prescription Technology Solutions | $17M+88.9% | $9M— | —— | —— | |
| Severance and employee-related costs, net by Business | |||||
| North American Pharmaceutical | $9M+400% | -$3M-143% | $7M— | —— | |
| Restructuring Charges by Business | |||||
| Medical-Surgical Solutions | $43M-78.9% | $204M+1,755% | $11M+10.0% | $10M+11.1% | |
| North American Pharmaceutical | $24M— | —— | $20M— | —— | |
| Prescription Technology Solutions | $20M+66.7% | $12M+9.1% | $11M-74.4% | $43M+72.0% | |
| Payments for Restructuring by Business | |||||
| Medical-Surgical Solutions | $133M+34.3% | $99M+662% | $13M+333% | $3M-50.0% | |
| Oncology & Multispecialty | $0-100% | $2M— | —— | —— | |
| Exit and other-related costs by Business | |||||
| Medical-Surgical Solutions | $37M-30.2% | $53M+342% | $12M+300% | $3M-40.0% | |
| North American Pharmaceutical | $3M0.0% | $3M0.0% | $3M— | —— | |
| Goodwill, transfer to held-for-sale by Business | |||||
| Medical-Surgical Solutions | $0— | —— | —— | —— | |
| Oncology & Multispecialty | $9M— | $0— | —— | —— | |
| Prescription Technology Solutions | $0— | —— | —— | —— | |
| Asset impairments and accelerated depreciation by Business | |||||
| North American Pharmaceutical | $12M— | —— | $10M— | —— | |
| Goodwill by Business | |||||
| Medical-Surgical Solutions | $10.03B-0.3% | $10.06B+2.5% | $9.81B0.0% | $9.81B0.0% | |
| Prescription Technology Solutions | $8.26B+2.0% | $8.1B+0.7% | $8.04B+13.3% | $7.09B+15.0% | |
| Goodwill acquired by Business | |||||
| Medical-Surgical Solutions | $0— | —— | —— | —— | |
| Total long-lived assets by Geography | |||||
| Foreign | $1.1B— | —— | —— | —— | |
| United States | $12.35B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does McKesson break its business down?
- McKesson (MCK) reports total revenues by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
